Indications and uses
Immune Support during times of: seasonal colds and flu
Immune Support during times of: seasonal colds and flu
Turn tube upside down and rotate cap to release pellets into cap. Unscrew cap and without touching pellets tip them into the mouth under the tongue. Allow to dissolve Take 15 minutes before meals.
ANANASSA SATIVA 3X RELIEVES INFLAMMATION
GCSF 4C, 9C, 15C, 30C, INTERFERON GAMMA 4C IMMUNE SUPPORT
INTERLEUKIN 1 BETA 5C, INTERLEUKIN 2 5C, 7C, INTERLEUKIN 4 4C IMMUNE SUPPORT
INTERLEUKIN 6 7C, 9C, 15C, THYMUS GLAND 4C IMMUNE SUPPORT
HYDROCOTYLE ASIATICA 3X RELIEVES COLD SYMPTOMS
LYMPHATIC VESSEL 4C, MOUNTAIN CRANBERRY 3X RELIEVES INFLAMMATION, SWELLING, RESPIRATORY CONGESTION
MEDULLA OSSIS 4C RELIEVES NASAL CONGESTION
Immune Support during times of:
If pregnant or breast-feeding ask a health care professional before use.
Keep this and all medicines out of reach of children
Questions?: info@gunainc.com
tel. (484) 223-3500
Inactive ingredient: Sucrose.
Immune support suring times of:
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| bd1801bf-1b8e-49c6-894d-a4af5821c1ab | Product name | 1 | 20161129 |
| d45267e3-883a-4760-85b5-ebc565c21683 | Product name | 1 | 20150910 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17089-076-20 | 2020-03-13 | C162847 | 48780-1 | 9d75b9d0-3fdc-f424-e053-dadaa90a57ce | CITOMIX |
| 17089-076-20 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-3fdc-f424-e053-dadaa90a57ce | CITOMIX |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17089-076-20 | CITOMIX | 2 in 1 BOX | PELLET | 2 | 8 | |
| 17089-076-20 | CITOMIX | 4 g in 1 TUBE | PELLET | 4 | 8 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17089-076 | CITOMIX (ALDESLEUKIN - BINETRAKIN - CANAKINUMAB - CENTELLA ASIATICA - CRANBERRY - HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - INTERFERON GAMMA-1B - LENOGRASTIM - PINEAPPLE - SUS SCROFA BONE MARROW - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA THYMUS -) PELLET [GUNA SPA] | 8 | Current NDC, Legacy NDC, 2 package rows | 20250112_23886c49-5992-4a59-af52-e24eb3c9fbc5.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ALDESLEUKIN | ACTIVE INGREDIENT | M89N0Q7EQR | 3 | |
| BINETRAKIN | ACTIVE INGREDIENT | 751635Z921 | 3 | |
| CANAKINUMAB | ACTIVE INGREDIENT | 37CQ2C7X93 | 3 | |
| CENTELLA ASIATICA | ACTIVE INGREDIENT | 7M867G6T1U | 3 | |
| CRANBERRY | ACTIVE INGREDIENT | 0MVO31Q3QS | 3 | |
| HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) | ACTIVE INGREDIENT | 92QVL9080Y | 3 | |
| INTERFERON GAMMA-1B | ACTIVE INGREDIENT | 21K6M2I7AG | 3 | |
| LENOGRASTIM | ACTIVE INGREDIENT | 6WS4C399GB | 3 | |
| PINEAPPLE | ACTIVE INGREDIENT | 2A88ZO081O | 3 | |
| SUS SCROFA BONE MARROW | ACTIVE INGREDIENT | VP2CN2G7Y8 | 3 | |
| SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE | ACTIVE INGREDIENT | 308LM01C72 | 3 | |
| SUS SCROFA THYMUS | ACTIVE INGREDIENT | 7B69B0BD62 | 3 | |
| ALDESLEUKIN | ACTIVE MOIETY | M89N0Q7EQR | 3 | |
| BINETRAKIN | ACTIVE MOIETY | 751635Z921 | 3 | |
| CANAKINUMAB | ACTIVE MOIETY | 37CQ2C7X93 | 3 | |
| CENTELLA ASIATICA | ACTIVE MOIETY | 7M867G6T1U | 3 | |
| CRANBERRY | ACTIVE MOIETY | 0MVO31Q3QS | 3 | |
| HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) | ACTIVE MOIETY | 92QVL9080Y | 3 | |
| INTERFERON GAMMA-1B | ACTIVE MOIETY | 21K6M2I7AG | 3 | |
| LENOGRASTIM | ACTIVE MOIETY | 6WS4C399GB | 3 | |
| PINEAPPLE | ACTIVE MOIETY | 2A88ZO081O | 3 | |
| SUS SCROFA BONE MARROW | ACTIVE MOIETY | VP2CN2G7Y8 | 3 | |
| SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE | ACTIVE MOIETY | 308LM01C72 | 3 | |
| SUS SCROFA THYMUS | ACTIVE MOIETY | 7B69B0BD62 | 3 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17089-076 | 17089-076-20 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| PINEAPPLE | 2A88ZO081O | ACTIB |
| LENOGRASTIM | 6WS4C399GB | ACTIB |
| CENTELLA ASIATICA | 7M867G6T1U | ACTIB |
| INTERFERON GAMMA-1B | 21K6M2I7AG | ACTIB |
| CANAKINUMAB | 37CQ2C7X93 | ACTIB |
| ALDESLEUKIN | M89N0Q7EQR | ACTIB |
| BINETRAKIN | 751635Z921 | ACTIB |
| HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) | 92QVL9080Y | ACTIB |
| SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE | 308LM01C72 | ACTIB |
| SUS SCROFA BONE MARROW | VP2CN2G7Y8 | ACTIB |
| CRANBERRY | 0MVO31Q3QS | ACTIB |
| SUS SCROFA THYMUS | 7B69B0BD62 | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CITOMIX | ALDESLEUKIN - BINETRAKIN - CANAKINUMAB - CENTELLA ASIATICA - CRANBERRY - HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - INTERFERON GAMMA-1B - LENOGRASTIM - PINEAPPLE - SUS SCROFA BONE MARROW - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA THYMUS - | Guna spa | 23886c49-5992-4a59-af52-e24eb3c9fbc5 | 2025-01-10 | Warnings | 17089-076-20 17089-076 17089007620 2b563c1a-771f-eb3f-e063-6394a90a618f 23886c49-5992-4a59-af52-e24eb3c9fbc5 |
Adverse event summaries are temporarily unavailable. Other product information remains available.